Paptawan Thongdee
Overview
Explore the profile of Paptawan Thongdee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taveepanich S, Chayajarus K, Jittimanee J, Phusri N, Thongdee P, Sawatdee K, et al.
Heliyon
. 2024 Oct;
10(19):e38213.
PMID: 39397930
Background: Iron overload and inflammation are severe conditions that can lead to various chronic diseases. However, the current iron chelator drugs have their limitations. The phytochemical compounds from herbals, such...
2.
Pakamwong B, Thongdee P, Kamsri B, Phusi N, Taveepanich S, Chayajarus K, et al.
J Chem Inf Model
. 2024 Jul;
64(15):5991-6002.
PMID: 38993154
is the single most important global infectious disease killer and a World Health Organization critical priority pathogen for development of new antimicrobials. DNA gyrase is a validated target for anti-TB...
3.
Thongdee P, Nagura Y, Sabishiro H, Phusi N, Sukchit D, Kamsri P, et al.
J Biomol Struct Dyn
. 2023 Dec;
43(3):1192-1205.
PMID: 38063158
Tuberculosis (TB), the second leading infectious killer, causes serious public health problems worldwide. To develop novel anti-TB agents, many biochemical studies have targeted the subunit B of DNA gyrase (GyrB),...
4.
Pornprom T, Phusi N, Thongdee P, Pakamwong B, Sangswan J, Kamsri P, et al.
Talanta
. 2023 Sep;
267:125210.
PMID: 37717539
Tuberculosis (TB) currently remains a major life-threatening disease as it can be fatal if not treated properly or in a timely manner. Herein, we first describe a disposable and cost-effective...
5.
Kamsri B, Pakamwong B, Thongdee P, Phusi N, Kamsri P, Punkvang A, et al.
J Chem Inf Model
. 2023 Apr;
63(9):2707-2718.
PMID: 37074047
Mutations in DNA gyrase confer resistance to fluoroquinolones, second-line antibiotics for infections. Identification of new agents that inhibit DNA gyrase ATPase activity is one strategy to overcome this. Here, bioisosteric...
6.
Phusi N, Hashimoto Y, Otsubo N, Imai K, Thongdee P, Sukchit D, et al.
Comput Biol Med
. 2022 Dec;
152:106434.
PMID: 36543008
2-trans enoyl-acyl carrier protein reductase (InhA) is a promising target for developing novel chemotherapy agents for tuberculosis, and their inhibitory effects on InhA activity were widely investigated by the physicochemical...
7.
Thongdee P, Hanwarinroj C, Pakamwong B, Kamsri P, Punkvang A, Leanpolchareanchai J, et al.
J Chem Inf Model
. 2022 Aug;
62(24):6508-6518.
PMID: 35994014
protein kinase B (PknB) is essential to mycobacterial growth and has received considerable attention as an attractive target for novel anti-tuberculosis drug development. Here, virtual screening, validated by biological assays,...
8.
Hanwarinroj C, Thongdee P, Sukchit D, Taveepanich S, Kamsri P, Punkvang A, et al.
J Mol Graph Model
. 2022 Jun;
115:108231.
PMID: 35667143
Serine/threonine protein kinase B (PknB) is essential to Mycobacterium tuberculosis (M. tuberculosis) cell division and metabolism and a potential anti-tuberculosis drug target. Here we apply Hologram Quantitative Structure Activity Relationship...
9.
Pakamwong B, Thongdee P, Kamsri B, Phusi N, Kamsri P, Punkvang A, et al.
J Chem Inf Model
. 2022 Mar;
62(7):1680-1690.
PMID: 35347987
DNA gyrase manipulates the DNA topology using controlled breakage and religation of DNA driven by ATP hydrolysis. DNA gyrase has been validated as the enzyme target of fluoroquinolones (FQs), second-line...